High-dose lovastatin decreased basal prostacyclin production in cultured endothelial cells

Prostaglandins and Other Lipid Mediators

Volumn 89, Issue 1-2, 2009, Pages 1-7

  Zhou, Qi ^a   Zhou, Yi ^b   Kummerow, Fred A ^a  

^a Burnsides Research Laboratory   (United States)

^b WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

27OHC; Arachidonic acid; Cyclooxygenase 1; Lovastatin; PLA2; Prostacyclin

Indexed keywords

26 HYDROXYCHOLESTEROL; ARACHIDONIC ACID; CALCIUM 45; CHOLESTEROL; CHOLINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FARNESOL; GERANYLGERANIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; MEVALONIC ACID; MEVINOLIN; PHOSPHOLIPASE A2; PROSTACYCLIN;

ARTICLE; CALCIUM TRANSPORT; CELL CULTURE; CELL LEVEL; CHOLESTEROL SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL;

ANIMALS; CELLS, CULTURED; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; EPOPROSTENOL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; TIME FACTORS;

EID: 67349128646     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2008.12.005     Document Type: Article

References (42)

1. Needleman P., Turk J., Jakschilk B.A., Morrison A.R., and Leflowich J.B. Arachidonic acid metabolism. Annu Rev Biochem 55 (1986) 69-102
2. Smith W.L. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 263 (1992) F181-F191
3. Moncada S., and Vane J. Arachidonic acid metabolites and the interactions between platelets and blood vessel walls. N Engl Med 300 (1979) 1142-1147
4. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33 (1992) 1569-1582
5. Havel R.J., and Rapaport E. Management of primary hyperlipidemia. N Engl J Med 332 (1995) 1491-1498
6. MAAS Investigators. Effect of simvastatin on coronary atheroma: the multicenter anti-atheroma study (MAAS). Lancet 1994;344:633-8.
7. NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel II). JAMA 1993;269:3015-23.
8. 2 production in rat liver cells. Lipids Health Dis (2003) 2
9. Hrboticky N., Tang L., Zimmer B., Lux I., and Weber P.C. Lovastatin increases arachidonic acid levels and stimulates thromboxane synthesis in human liver and monocytic cell lines. J Clin Invest 93 (1994) 195-203
10. Seeger H., Mueck A.O., and Lippert T.H. Fluvastatin increases prostacyclin and decreases endothelin production by human umbilical vein endothelial cells. Int J Clin Phamacol Ther 38 (2000) 270-272
11. Hernandez-Presa M.A., Martin-Ventura J.L., Ortego M., et al. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis. 160 (2002) 49-58
12. 2 release induced by HDL in human VSMC: effect on Cox-2 up-regulation and MAPK signaling pathways activated by HDL. Atherosclerosis 174 (2004) 305-313
13. Degraeve F., Bolla M., Blaie S., et al. Modulation of COX-2 expression by statins in human aortic smooth muscle cells. J Biol Chem 276 (2001) 46849-46855
14. Inoue I., Goto S., Mizotani K., et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect reduction of MRNA levels for interleukin-1B, interleukin-6, cyclooxygenase-2, and p22phoxy by regulation of peroxisone prolifrator-activated receptor a (PPARa) in primary endothelial cells. Life Sci 67 (2000) 863-876
15. 2 knockout mouse. J Neurochem 87 (2003) 1471-1477
16. Pan H.Y., DeVault A.R., Wang-Iverson D., Ivashkiv E., Swanson B.N., and Sugerman A.A. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 30 (1990) 1128-1135
17. 2 and arachidonic acid to prostacyclin by cultured human endothelial cells. J Biol Chem 253 (1978) 7138-7141
18. Zhou Q., Jimi S., Smith T.L., and Kummerow F.A. The effect of 25-hydroxycholesterol on accumulation of intracellular calcium. Cell Calcium 12 (1991) 467-476
19. Folch J., Lees M., and Sloane-Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226 (1957) 497-509
20. Glick D., Fell B.F., and Sjolin K.E. Spectrophotometric determination of nanogram amounts of total cholesterol in microgram quantities of tissue or microliter volumes of serum. Anal Chem 36 (1964) 1119-1121
21. 2 mediates arachidonoyl phospholipid hydrolysis in immortalized rat brain endothelial cells stimulated by oxidized LDL. Biochim Biophys Acta 1585 (2002) 19-29
22. Bellosta S., Bernini F., Ferri N., et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 137 Suppl. (1998) S101-S109
23. Briand S.I., Bernier S.G., and Guilemette G. Calcium-calmodulin plays a major role in bradykinin-induced arachidonic acid release by bovine aortic endothelial cells. J Cell Biochem 63 (1996) 292-301
24. Millanvoye-Van Brussel E., David-Dufilho M., Pham T.D., Iouzalen L., and Aude Devynck M. Regulation of arachidonic acid release by calcium influx in human endothelial cells. J Vasc Res 36 (1999) 235-244
25. Panini S.R., Yang L., Rusinol A.E., Sinensky M.S., Bonventre J.V., and Leslie C.C. Arachidonate metabolism and the signaling pathway of induction of apoptosis by oxidized LDL/oxysterol. J Lipid Res 42 (2001) 1678-1686
26. Zhou Q., and Kummerow F.A. Modifying effect of 26-hydroxycholesterol on low-magnesium-induced atherosclerotic changes in the cultured human arterial smooth muscle cell. Magnesium Res 6 (1993) 121-126
27. ++ uptake and lipid content in cultured human arterial smooth muscle cells treated with 26-hydroxycholesterol. Artery 21 (1994) 182-192
28. ++ content in cultured smooth muscle cells. Biomed Environ Sci 10 (1997) 369-376
29. Williams C.S., and DuBois R.N. Prostaglandin endoperoxide synthase: why two isoforms?. Am J Physiol 270 (1996) G393-G400
30. Gierse J.K., McDonald J.J., Hauser S.D., Rangwala S.H., Koboldt C.M., and Seibert K. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem 271 (1996) 15810-15814
31. Siomboing X., D'Hondt O., luyckx M., Gressier B., Dine T., and Brunet C. A model with original conditions and materials to test potential inhibitors of cyclooxygenase-2 versus cyclooxygenase-1 in isolated human blood cells. Methods Find Exp Clin Pharmacol 25 (2003) 175-181
32. 2 balance: pathophysiological and therapeutic implications. Br Med Bull 39 (1983) 271-276
33. Lacoste L., Lam J.Y., Hung J., Letchacovski G., Solymoss C.B., and Waters D. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 92 (1995) 3172-3177
34. Alfon J., Pueyo Palazon C., Royo T., and Badimon L. Effects of statins in thrombosis and aortic lesion development in a dyslipidemic rabbit model. Thromb Haemost 81 (1999) 822-827
35. Alfon J., Royo T., Garcia-Moll X., and Badimon L. Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin. Arterioscler Thromb Vasc Biol 19 (1999) 1812-1817
36. 2 with pravastatin therapy for hypercholesterolemia. J Assoc Acad Minor Phys 13 (2002) 23-26
37. Schror K., Lobel P., and Steinhagen-Thiessen E. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type Iia hypercholesterolemia. Eicosanoids 2 (1989) 39-45
38. Lial J.K. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 86 (2002) 5-18
39. Wiklund O., Mattsson-Hulten L., Hurt-Camejo E., and Oscarsson J. Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med 251 (2002) 338-347
40. Kume N., and Gimbrone Jr. M.A. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest 93 (1994) 907-911
41. Quinn M.T., Parthasarathy S., and Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherosclerosis. Proc Natl Acad Sci U S A 85 (1988) 2805-2809
42. 2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 25 (2005) 923-931